Peapod Lane Capital LLC Purchases Shares of 144,743 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Peapod Lane Capital LLC purchased a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 144,743 shares of the company's stock, valued at approximately $806,000. Peapod Lane Capital LLC owned 0.31% of 4D Molecular Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Barclays PLC lifted its position in shares of 4D Molecular Therapeutics by 141.0% during the 3rd quarter. Barclays PLC now owns 114,848 shares of the company's stock valued at $1,241,000 after acquiring an additional 67,202 shares during the period. Novo Holdings A S increased its stake in 4D Molecular Therapeutics by 7.1% in the third quarter. Novo Holdings A S now owns 1,500,000 shares of the company's stock valued at $16,215,000 after purchasing an additional 100,000 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of 4D Molecular Therapeutics during the third quarter valued at about $40,000. Braidwell LP grew its stake in shares of 4D Molecular Therapeutics by 231.7% in the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company's stock valued at $13,247,000 after buying an additional 855,990 shares during the period. Finally, State Street Corp increased its position in 4D Molecular Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,116,508 shares of the company's stock valued at $22,879,000 after buying an additional 37,232 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, February 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Saturday, February 1st. Bank of America lowered their price objective on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. BMO Capital Markets cut shares of 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $40.00 to $15.00 in a report on Monday, January 13th. Finally, Leerink Partners lowered their target price on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating on the stock in a report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.13.

4D Molecular Therapeutics Trading Up 3.4 %

Shares of FDMT stock traded up $0.16 during trading on Monday, hitting $4.88. The company's stock had a trading volume of 751,146 shares, compared to its average volume of 786,790. The business has a fifty day moving average of $5.60 and a 200-day moving average of $9.30. The company has a market cap of $225.60 million, a PE ratio of -1.71 and a beta of 2.81. 4D Molecular Therapeutics, Inc. has a 52 week low of $4.41 and a 52 week high of $36.25.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.